Prophylactic HIV Drug Market: Racing Towards a Horizon of US$ 48.8 Billion by 2033

The prophylactic HIV drugs industry size  is projected to be worth US$32,516.1 million in 2023 and US$31,278.5 million in 2022.

Growth in the market is primarily due to increased R&D investment in HIV clinical trials by pharmaceutical and biotechnology companies, increased HIV drug approvals, and an increase in the prevalence of HIV in the population. According to Future Market Insights, the market will grow at a CAGR of 4.1% between 2023 and 2033, reaching around US$ 48,822.4 million by 2033.

In 2021, the global market for prophylactic HIV drugs is expected to be worth around US$ 30 billion. Because of the increasing prevalence of HIV infection worldwide and growing HIV awareness In terms of AIDS prevention, the demand for prophylactic HIV drugs increased at a 4% CAGR between 2022 and 2032, reaching more than US$ 40 billion in 2028.

For many years, HIV has been a primary cause of death worldwide, affecting millions of individuals. The virus impairs affected people’s immune systems, making them vulnerable to a variety of illnesses and malignancies. While there is no permanent cure for HIV, it can be managed by improving access to appropriate prevention, diagnosis, treatment, and care.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-9582

The rising emphasis on HIV prevention is a primary driver of demand for preventive HIV drugs. These sophisticated therapies are precisely developed to prevent HIV infection in specific conditions, and they are especially successful in preventing HIV transmission via sex and injection drug use.

Pre-exposure prophylaxis (PrEP) efficacy has grown, leading to increased global usage of this preventative strategy. PrEP reduces the risk of HIV transmission through intercourse and injectable drug use by approximately 99% and 74%, respectively, according to the Centres for Disease Control and Prevention (CDC). Because of their efficiency in preventing and controlling HIV infection, Prophylactic HIV Drugs such as antiretroviral (ARV) are also gaining popularity.

The growing public awareness of HIV and the benefits of Prophylactic HIV Drugs are expected to drive up sales during the forecast period. By making these drugs more accessible, the hope is to help reduce the incidence of HIV and improve the quality of life for those living with the disease.

What are the Challenges Faced by Prophylactic HIV Drugs Market?

Despite its positive outlook, the market for HIV prevention drugs confronts a few hurdles. Some of these issues include side effects from prophylactic HIV treatments, stringent government approval for these drugs, and a lack of information of these therapeutics in low-income emerging economies.

Prophylactic HIV Drugs have been linked to a variety of side effects, including headaches, depression, nausea, vomiting, and stomach discomfort. As a result, many people avoid using these therapies. As a result, the market for HIV preventive drugs is shrinking.

How Will Prophylactic HIV Drugs Market Fare in Europe?

Due to rising HIV infection rates and increased acceptance of innovative treatments, the Europe Prophylactic HIV Drugs market is likely to rise rapidly over the forecast period.

Over the last few decades, there has been a large increase in HIV incidence in European countries such as the United Kingdom, Germany, and France due to a variety of circumstances. nearly the previous three decades, nearly 2.2 million persons in the WHO European Region have been diagnosed and reported with HIV, according to the European Centre for Disease Prevention and Control. As a result, the region’s market for preventive HIV drugs is growing.

Furthermore, the presence of leading manufacturers such as ViiV Health is positively impacting the growth of the European market for Prophylactic HIV Drugs.

Market Competition

Some of the leading manufacturers of Prophylactic HIV Drugs include Gilead Sciences, Inc, Merck Sharp & Dohme Corp., Merck & Co. Inc., Mylan NV, Cipla Inc., Genentech Inc., Bristol-Myers Squibb Company, and Johnson & Johnson Health Care Systems Inc.

These key players are rigorously investing in research and development to advance in HIV therapeutics. They have adopted strategies such as new product launches and approvals, mergers, partnerships, acquisitions, launching awareness campaigns, etc. to expand their customer bases as well as to gain an upper hand in the global Prophylactic HIV Drugs market. For instance, in December 2021, the US Food and Drug Administration approved first injectable treatment “Apretude” for HIV pre-exposure prevention.

More insights available

North America is a mature HIV drugs market, with a high prevalence rate and a well-established healthcare system. The United States accounts for a significant portion of the region’s HIV drugs market, with a high adoption rate for antiretroviral therapies. The availability of insurance coverage for HIV treatment and a robust research and development ecosystem further contribute to the market growth.

Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-9582

Key Segments Profiled in the Prophylactic HIV Drugs Industry Survey

By Drug Class:

  • Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)
  • Integrase Inhibitor

By Distributional Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Drug Stores

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Ronak Shah

Associate Vice President at Future Market Insights is deeply committed to uncovering actionable insights for consumer and food and beverage players. She brings a unique blend of analysis, industry trends, and consumer behavior to put data into perspective.

What she makes out of data becomes a delight to read. She has authored many opinions, including for publications like Process Industry Informer and Spinal Surgery News, as she understands the market pulse and consumers' shifting preferences.

She likes to bring experts to a roundtable to weigh the impact of a trend on an industry. Catch up with her discussion on the impact of AI in packaging.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these